— Perrigo Company plc (NYSE: PRGO) reported Q3 2019 earnings of $1.04 per share, vs. $0.93 expected.
— Sales grew 5.1% to $1.2 billion, vs. $1.2 billion expected.
— Worldwide Consumer net sales increased 3.3% to $961 million.
— Prescription Pharmaceuticals sales improved 13.6% to $230 million.
— FY19 GAAP EPS is expected to be $2.01-2.21.
— FY19 adjusted EPS is expected to be $3.85-4.05.
— PRGO shares gained 0.98% following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
